Newron Pharmaceuticals S.p.A.

BRIEF

published on 12/08/2025 at 07:05, 10 days 13 hours ago

Newron lance une étude de phase III aux États-Unis sur l'événamide pour la schizophrénie

Schizophrénie Essai Clinique Newron Pharmaceuticals Evenamide Étude De Phase III
BRIEF

published on 12/08/2025 at 07:05, 10 days 13 hours ago

Newron Launches US Phase III Study on Evenamide for Schizophrenia

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide Phase III Study
PRESS RELEASE

published on 12/08/2025 at 07:00, 10 days 13 hours ago

Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS 2
BRIEF

published on 10/02/2025 at 07:05, 2 months 16 days ago

Newron Pharmaceuticals Highlights Evenamide at ECNP Congress 2025

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress
BRIEF

published on 10/02/2025 at 07:05, 2 months 16 days ago

Newron Pharmaceuticals présente l'Evenamide au congrès ECNP 2025

Schizophrénie Essai Clinique Newron Pharmaceuticals Evenamide Congrès De L'ECNP
PRESS RELEASE

published on 10/02/2025 at 07:00, 2 months 16 days ago

Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Newron Pharmaceuticals to present new analyses and updates on evenamide as treatment for schizophrenia at the 38th ECNP Congress 2025

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress
BRIEF

published on 09/16/2025 at 07:05, 3 months 2 days ago

Newron Pharmaceuticals Unveils H1 2025 Results and Strategic Advancements

Strategic Partnerships Clinical Trials Newron Pharmaceuticals Evenamide Schizophrenia Treatment
BRIEF

published on 09/16/2025 at 07:05, 3 months 2 days ago

Newron Pharmaceuticals dévoile ses résultats du premier semestre 2025 et ses avancées stratégiques

Partenariats Stratégiques Essais Cliniques Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie
PRESS RELEASE

published on 09/16/2025 at 07:00, 3 months 2 days ago

Newron presents H1 2025 results and provides business update
Newron Pharmaceuticals S.p.A. presents H1 2025 financial results and business update, focusing on evenamide therapy for treatment-resistant schizophrenia patients and strategic partnerships

Business Update Newron Pharmaceuticals Schizophrenia Treatment H1 2025 Results Evenamide Therapy
BRIEF

published on 09/05/2025 at 07:05, 3 months 13 days ago

Newron Pharmaceuticals dévoilera ses résultats sur l'Evenamide au WCBP 2025

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Mises À Jour Des Essais Cliniques Modulation Du Glutamate

1 2 ... 8

Published on 12/18/2025 at 18:00, 2 hours 24 minutes ago

PPX Mining Announces 2025 AGM Results
Published on 12/18/2025 at 15:00, 5 hours 24 minutes ago

Vox Royalty Acquires Feasibilty-Stage Stockman Copper-Gold Royalty in Australia
Published on 12/18/2025 at 14:31, 5 hours 53 minutes ago

Worksport Reports Highest Monthly Revenue in Company History
Published on 12/18/2025 at 14:00, 6 hours 24 minutes ago

Route1 Announces Provisional Patent Application
Published on 12/18/2025 at 14:00, 6 hours 24 minutes ago

LQR House Announces $6.52 Million Registered Direct Offering

View all ACCESSWIRE

Published on 12/18/2025 at 20:09, 15 minutes ago

EQS-Adhoc: The Grounds Real Estate Development AG: Conversion of the EUR 17 million bond issued in 2023/2024 into a hybrid bond
Published on 12/18/2025 at 19:30, 54 minutes ago

Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE EN REPONSE ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES DANS LE CADRE DE L’OFFRE PUBLIQUE DE RETRAIT
Published on 12/18/2025 at 19:30, 54 minutes ago

Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE D’INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES , NOTAMMENT JURIDIQUES, FINANCIERE DE PHAST INVEST
Published on 12/18/2025 at 18:48, 1 hour 36 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/18/2025 at 18:45, 1 hour 39 minutes ago

PATRIMOINE ET COMMERCE: PROJET D’AUGMENTATIONS DE CAPITAL DE PATRIMOINE & COMMERCE D’UN MONTANT DE 30 MILLIONS D’EUROS

View all EQS

Published on 12/18/2025 at 18:30, 1 hour 54 minutes ago

Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 1 hour 54 minutes ago

Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 2 hours 39 minutes ago

Cie du Bois Sauvage: Vernietiging eigen aandelen
Published on 12/18/2025 at 17:45, 2 hours 39 minutes ago

Damartex réaffirme son éligibilité au PEA-PME
Published on 12/18/2025 at 17:45, 2 hours 39 minutes ago

Cie du Bois Sauvage : Cancellation of own shares

View all LES ECHOS COMFI WIRE

News